Cyclerion Therapeutics, Inc. Stock

Equities

CYCN

US23255M2044

Biotechnology & Medical Research

Delayed Nasdaq 10:37:03 2024-07-16 EDT 5-day change 1st Jan Change
3.03 USD +3.77% Intraday chart for Cyclerion Therapeutics, Inc. +31.73% -9.55%
Sales 2022 1.62 2.22 Sales 2023 - Capitalization 8.19M 11.21M
Net income 2022 -44M -60.23M Net income 2023 -5M -6.84M EV / Sales 2022 17,563,610 x
Net cash position 2022 13.38 18.32 Net cash position 2023 7.57 10.36 EV / Sales 2023 -
P/E ratio 2022
-0.65 x
P/E ratio 2023
-1.49 x
Employees 1
Yield 2022 *
-
Yield 2023
-
Free-Float 72.47%
More Fundamentals * Assessed data
Dynamic Chart
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cyclerion Therapeutics, Inc. Appoints Regina Graul as President CI
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments CI
Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer CI
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal MT
Tisento Therapeutics, Inc. announced that it has received $81 million in funding from Cyclerion Therapeutics, Inc., Invus, Polaris, and other investors CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Cyclerion Therapeutics, Inc. Announces Resignation of Cheryl Gault as Chief Operating Officer CI
Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding CI
Cyclerion Therapeutics to Implement 1-for-20 Reverse Stock Split MT
Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Cyclerion Therapeutics to Sell Zagociguat, CY3018 Assets to New Private Company MT
More news
1 day+3.77%
1 week+31.73%
Current month+31.74%
1 month+8.68%
3 months-4.72%
6 months-20.89%
Current year-9.55%
More quotes
1 week
2.24
Extreme 2.24
3.94
1 month
1.90
Extreme 1.9
3.94
Current year
1.90
Extreme 1.9
4.30
1 year
1.75
Extreme 1.7501
5.25
3 years
1.75
Extreme 1.7501
84.60
5 years
1.75
Extreme 1.7501
296.60
10 years
1.75
Extreme 1.7501
457.00
More quotes
Managers TitleAgeSince
President 47 12-03
Director/Board Member 60 19-03-31
Members of the board TitleAgeSince
Chairman 70 21-04-25
Director/Board Member 60 19-03-31
Director/Board Member 71 22-07-24
More insiders
Date Price Change Volume
24-07-16 3.03 +3.77% 612
24-07-15 2.92 -12.05% 3,343
24-07-12 3.32 -1.78% 4,453
24-07-11 3.38 -11.29% 38,326
24-07-10 3.81 +65.64% 18,886

Delayed Quote Nasdaq, July 16, 2024 at 10:37 am

More quotes
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
More about the company